rgx-111
·Code: RGX-111
rgx-111: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| REGENXBIO Inc. (RGNX) | Phase 1/Phase 2 |
FDA Decisions
FDA_MeetingFDA placed the Company's IND for the Phase I/II trial of RGX-111 for Mucopolysaccharidosis type I on clinical hold.(RGNX)
Frequently asked questions
Who is developing rgx-111?
rgx-111 is being developed by REGENXBIO Inc..
What is rgx-111's latest FDA decision?
The most recent tracked FDA decision for rgx-111 is FDA_Meeting for FDA placed the Company's IND for the Phase I/II trial of RGX-111 for Mucopolysaccharidosis type I on clinical hold., dated January 28, 2026.
Get deeper analysis on rgx-111
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis